Drug Profile
Research programme: glioblastoma multiforme therapeutics - Opal Oncology
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Opal Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 15 Sep 2023 Preclinical development for Glioblastoma is ongoing in the United Kingdome (Opal Oncology pipeline, September 2023)
- 15 Sep 2023 Opal Oncology intends to file regulatory approval for a clinical trial (Opal Oncology website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Glioblastoma in United Kingdom